Is it time for China to prioritize pan-genotypic regimens for treating patients with hepatitis C?

Cost Eff Resour Alloc · 2024 · PMC10848349 · PMID 38321475

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

When the willingness-to-pay exceeded $931.1, there was an increasing trend in the probability that pan-genotypic regimen was more cost-effective, ranging from 50% to 99.9%.

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.